NDAC Support For Galderma's Acne Drug OTC Approval Comes With Advice On Evaluating Switches
This article was originally published in The Tan Sheet
Executive Summary
FDA's OTC division uses the NDAC meeting on Galderma's Differin Gel switch proposal to ask for input on evaluating future NDAs for other switches that would introduce new risks to the OTC space.